Skip to content
TrialScanner

NCT02575404

GR-MD-02 Plus Pembrolizumab in Melanoma, Non-small Cell Lung Cancer, and Squamous Cell Head and Neck Cancer Patients

Phase 1CompletedGALTCollaborator

Registry record

Lead sponsor
Providence Health & Services
Conditions
Melanoma; Non-Small Cell Lung Cancer; Squamous Cell Carcinoma of the Head and Neck
Primary completion
Jan 12, 2021Actual
Completion
Locked
Start
Locked
Enrollment
Locked
Interventions
Locked
Study type
Locked
Results on the registry
Locked
Record last updated
Locked

Open NCT02575404 on ClinicalTrials.gov

Enrollment, interventions, the start and completion dates and the change history are locked on 1 row here. Included with TrialScanner ($9.99 a month) and Signal8 Pro.

Unlock with TrialScanner

Recorded changes

0 changes recorded for this trial. The history, with each previous value, is part of TrialScanner.

Tracking since Nov 12, 2026. Changes before that date are not known to TrialScanner.

    NCT02575404: GR-MD-02 Plus Pembrolizumab... | TrialScanner